Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 44Biopsy 35Specimen Handling 34Magnetic Resonance Spectroscopy 30fludarabine 27aldesleukin 26Filgrastim 20Carboplatin 20Paclitaxel 19fludarabine phosphate 17Rituximab 17Sirolimus 16Cisplatin 16Temozolomide 15Radiotherapy 14Etoposide 14Bevacizumab 14Prednisone 13Gemcitabine 13Docetaxel 13Cytarabine 13Erlotinib Hydrochloride 12Fluorouracil 11Vorinostat 10Vincristine 10Sorafenib 10Electrocardiography 10Doxorubicin 10temsirolimus 9pembrolizumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × NIH × Amsacrine × Clear all
NCT00840684 2011-05-13

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
135 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡